New heart valve clip shows promise in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: To participate in this study, the patient must meet ALL of the following inclusion criteria: 1. 18 years of age or older, no gender limit; 2. New York Heart Association function class II, III or IV; 3. Moderate-to-severe or severe mitral valve regurgitation (grade≥3+) confirmed by transthoracic echocardiography or transesophageal echocardiography; 4. Patients with symptoms, or without symptoms but with left ventricular ejection fraction (LVEF) ≤ 60% or left ventricular end-systolic diameter (LVESD) ≥ 40 mm; 5. Patients are determined to be at a high risk for mitral valve surgery by cardiologists and should meet at least one of the following four criteria: 1. The American Society of Thoracic Surgeons (STS) predicted risk of mortality (PROM) is ≥ 6% for valve repair or is ≥ 8% for valve replacement; 2. Presence of ≥2 frailty indices (moderate to severe frailty); 3. Presence of ≥2 major organ dysfunctions that could not be improved after surgery; 4. Presence of other surgical high-risk comorbidities or factors as determined by the heart team. 6. Anatomically suitable for transcatheter mitral valve repair by edge-to-edge technique, can be treated by the investigational device, and transseptal catheterization and femoral vein access is determined to be feasible. 7. Patients who voluntarily participate in the study and sign the informed consent form (ICF), and are willing to undergo the required examinations and clinical follow-up visits. Exclusion Criteria: Patients will be excluded if ANY of the following conditions apply: 1. Patients who are unable to tolerate the treatment, including those with allergies or hypersensitivity to anticoagulant or antiplatelet agents; 2. Patients with contraindications to antithrombotic medication, or those with a history of cerebral hemorrhage, gastrointestinal hemorrhage, or hemorrhagic disorders within the past 3 months; 3. Patients known to have hypersensitivity or allergic reactions to nickel or titanium, cobalt, chromium, polyester, fluoropolymers, or contrast media; 4. Patients with active mitral valve endocarditis, rheumatic mitral valve disease, or mitral valve leaflet abnormalities (i.e. noncompliant, perforation) resulting from endocarditis or rheumatic heart disease; 5. Patients with active infections that significantly impact both the outcome of mitral valve transcatheter interventions and postoperative recovery; 6. Patients with intracardiac thrombus, vegetations, or masses identified by echocardiography; 7. Patients with coronary artery stenosis requiring revascularization, or those who have undergone coronary artery surgery within the past 30 days; 8. Patients with aortic stenosis or regurgitation requiring surgical intervention, as well as those with other cardiac conditions necessitating surgical treatment, as judged by clinicians; 9. Patients with unfavorable mitral valve anatomy for mitral valve clip placement, including but not limited to a mitral valve orifice area less than 4 cm²; 10. Patients with a history of heart transplantation, prior mitral valve surgery, or previous mitral valve transcatheter procedures; 11. Patients with severe pulmonary hypertension (pulmonary artery systolic pressure \> 70 mmHg, assessed by echocardiography or right heart catheterization, with right heart catheterization taking precedence in cases of concurrent measurement); 12. Patients with moderate-to-severe or severe right ventricular dysfunction as demonstrated by echocardiographic findings; 13. Patients with thrombi located in the inferior vena cava or femoral vein, presence of inferior vena cava filters, tortuous or obstructed venous anatomy, or other venous access limitations; 14. Patients unable to participate the 6-minute walk test; 15. Presence of diseases that may complicate the evaluation of treatment outcomes (e.g., coma, cancer, psychiatric disorders); 16. Pregnant or breastfeeding women, as well as women planning to become pregnant within the next 12 months; 17. Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator; 18. Patient is currently participating in another investigational drug or device clinical study; 19. Any other conditions deemed by the investigator to render the subject unsuitable for participation in the clinical study.